Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Angiongenesis Inhibitors and Stimulators Revenue 1.4 Market Analysis by Type 1.4.1 Global Angiongenesis Inhibitors and Stimulators Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Sprouting Angiogenesis 1.4.3 Intussusceptive Angiogenesis 1.5 Market by Application 1.5.1 Global Angiongenesis Inhibitors and Stimulators Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Clinics 1.5.4 Other 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Angiongenesis Inhibitors and Stimulators Market Perspective (2015-2026) 2.2 Angiongenesis Inhibitors and Stimulators Growth Trends by Regions 2.2.1 Angiongenesis Inhibitors and Stimulators Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Angiongenesis Inhibitors and Stimulators Historic Market Share by Regions (2015-2020) 2.2.3 Angiongenesis Inhibitors and Stimulators Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Angiongenesis Inhibitors and Stimulators Market Growth Strategy 2.3.6 Primary Interviews with Key Angiongenesis Inhibitors and Stimulators Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Angiongenesis Inhibitors and Stimulators Players by Market Size 3.1.1 Global Top Angiongenesis Inhibitors and Stimulators Players by Revenue (2015-2020) 3.1.2 Global Angiongenesis Inhibitors and Stimulators Revenue Market Share by Players (2015-2020) 3.1.3 Global Angiongenesis Inhibitors and Stimulators Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Angiongenesis Inhibitors and Stimulators Market Concentration Ratio 3.2.1 Global Angiongenesis Inhibitors and Stimulators Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Angiongenesis Inhibitors and Stimulators Revenue in 2019 3.3 Angiongenesis Inhibitors and Stimulators Key Players Head office and Area Served 3.4 Key Players Angiongenesis Inhibitors and Stimulators Product Solution and Service 3.5 Date of Enter into Angiongenesis Inhibitors and Stimulators Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Angiongenesis Inhibitors and Stimulators Historic Market Size by Type (2015-2020) 4.2 Global Angiongenesis Inhibitors and Stimulators Forecasted Market Size by Type (2021-2026) 5 Angiongenesis Inhibitors and Stimulators Breakdown Data by Application (2015-2026) 5.1 Global Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 5.2 Global Angiongenesis Inhibitors and Stimulators Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Angiongenesis Inhibitors and Stimulators Market Size (2015-2020) 6.2 Angiongenesis Inhibitors and Stimulators Key Players in North America (2019-2020) 6.3 North America Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) 6.4 North America Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 7 Europe 7.1 Europe Angiongenesis Inhibitors and Stimulators Market Size (2015-2020) 7.2 Angiongenesis Inhibitors and Stimulators Key Players in Europe (2019-2020) 7.3 Europe Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) 7.4 Europe Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 8 China 8.1 China Angiongenesis Inhibitors and Stimulators Market Size (2015-2020) 8.2 Angiongenesis Inhibitors and Stimulators Key Players in China (2019-2020) 8.3 China Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) 8.4 China Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 9 Japan 9.1 Japan Angiongenesis Inhibitors and Stimulators Market Size (2015-2020) 9.2 Angiongenesis Inhibitors and Stimulators Key Players in Japan (2019-2020) 9.3 Japan Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) 9.4 Japan Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size (2015-2020) 10.2 Angiongenesis Inhibitors and Stimulators Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) 10.4 Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 11 India 11.1 India Angiongenesis Inhibitors and Stimulators Market Size (2015-2020) 11.2 Angiongenesis Inhibitors and Stimulators Key Players in India (2019-2020) 11.3 India Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) 11.4 India Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Angiongenesis Inhibitors and Stimulators Market Size (2015-2020) 12.2 Angiongenesis Inhibitors and Stimulators Key Players in Central & South America (2019-2020) 12.3 Central & South America Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) 12.4 Central & South America Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Abbott Laboratories 13.1.1 Abbott Laboratories Company Details 13.1.2 Abbott Laboratories Business Overview and Its Total Revenue 13.1.3 Abbott Laboratories Angiongenesis Inhibitors and Stimulators Introduction 13.1.4 Abbott Laboratories Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020)) 13.1.5 Abbott Laboratories Recent Development 13.2 Adnexus Therapeutics 13.2.1 Adnexus Therapeutics Company Details 13.2.2 Adnexus Therapeutics Business Overview and Its Total Revenue 13.2.3 Adnexus Therapeutics Angiongenesis Inhibitors and Stimulators Introduction 13.2.4 Adnexus Therapeutics Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.2.5 Adnexus Therapeutics Recent Development 13.3 F. Hoffman-La Roche 13.3.1 F. Hoffman-La Roche Company Details 13.3.2 F. Hoffman-La Roche Business Overview and Its Total Revenue 13.3.3 F. Hoffman-La Roche Angiongenesis Inhibitors and Stimulators Introduction 13.3.4 F. Hoffman-La Roche Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.3.5 F. Hoffman-La Roche Recent Development 13.4 Genentech 13.4.1 Genentech Company Details 13.4.2 Genentech Business Overview and Its Total Revenue 13.4.3 Genentech Angiongenesis Inhibitors and Stimulators Introduction 13.4.4 Genentech Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.4.5 Genentech Recent Development 13.5 Amgen 13.5.1 Amgen Company Details 13.5.2 Amgen Business Overview and Its Total Revenue 13.5.3 Amgen Angiongenesis Inhibitors and Stimulators Introduction 13.5.4 Amgen Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.5.5 Amgen Recent Development 13.6 AstraZeneca 13.6.1 AstraZeneca Company Details 13.6.2 AstraZeneca Business Overview and Its Total Revenue 13.6.3 AstraZeneca Angiongenesis Inhibitors and Stimulators Introduction 13.6.4 AstraZeneca Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.6.5 AstraZeneca Recent Development 13.7 Novartis 13.7.1 Novartis Company Details 13.7.2 Novartis Business Overview and Its Total Revenue 13.7.3 Novartis Angiongenesis Inhibitors and Stimulators Introduction 13.7.4 Novartis Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.7.5 Novartis Recent Development 13.8 Pfizer 13.8.1 Pfizer Company Details 13.8.2 Pfizer Business Overview and Its Total Revenue 13.8.3 Pfizer Angiongenesis Inhibitors and Stimulators Introduction 13.8.4 Pfizer Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.8.5 Pfizer Recent Development 13.9 Chugai Pharmaceutical 13.9.1 Chugai Pharmaceutical Company Details 13.9.2 Chugai Pharmaceutical Business Overview and Its Total Revenue 13.9.3 Chugai Pharmaceutical Angiongenesis Inhibitors and Stimulators Introduction 13.9.4 Chugai Pharmaceutical Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.9.5 Chugai Pharmaceutical Recent Development 13.10 EntreMed 13.10.1 EntreMed Company Details 13.10.2 EntreMed Business Overview and Its Total Revenue 13.10.3 EntreMed Angiongenesis Inhibitors and Stimulators Introduction 13.10.4 EntreMed Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 13.10.5 EntreMed Recent Development 13.11 Eyetech 10.11.1 Eyetech Company Details 10.11.2 Eyetech Business Overview and Its Total Revenue 10.11.3 Eyetech Angiongenesis Inhibitors and Stimulators Introduction 10.11.4 Eyetech Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) 10.11.5 Eyetech Recent Development 14 Analyst's Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Angiongenesis Inhibitors and Stimulators Key Market Segments Table 2. Key Players Covered: Ranking by Angiongenesis Inhibitors and Stimulators Revenue Table 3. Ranking of Global Top Angiongenesis Inhibitors and Stimulators Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Angiongenesis Inhibitors and Stimulators Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Sprouting Angiogenesis Table 6. Key Players of Intussusceptive Angiogenesis Table 7. Global Angiongenesis Inhibitors and Stimulators Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 8. Global Angiongenesis Inhibitors and Stimulators Market Size by Regions (US$ Million): 2020 VS 2026 Table 9. Global Angiongenesis Inhibitors and Stimulators Market Size by Regions (2015-2020) (US$ Million) Table 10. Global Angiongenesis Inhibitors and Stimulators Market Share by Regions (2015-2020) Table 11. Global Angiongenesis Inhibitors and Stimulators Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 12. Global Angiongenesis Inhibitors and Stimulators Market Share by Regions (2021-2026) Table 13. Market Top Trends Table 14. Key Drivers: Impact Analysis Table 15. Key Challenges Table 16. Angiongenesis Inhibitors and Stimulators Market Growth Strategy Table 17. Main Points Interviewed from Key Angiongenesis Inhibitors and Stimulators Players Table 18. Global Angiongenesis Inhibitors and Stimulators Revenue by Players (2015-2020) (Million US$) Table 19. Global Angiongenesis Inhibitors and Stimulators Market Share by Players (2015-2020) Table 20. Global Top Angiongenesis Inhibitors and Stimulators Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Angiongenesis Inhibitors and Stimulators as of 2019) Table 21. Global Angiongenesis Inhibitors and Stimulators by Players Market Concentration Ratio (CR5 and HHI) Table 22. Key Players Headquarters and Area Served Table 23. Key Players Angiongenesis Inhibitors and Stimulators Product Solution and Service Table 24. Date of Enter into Angiongenesis Inhibitors and Stimulators Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 27. Global Angiongenesis Inhibitors and Stimulators Market Size Share by Type (2015-2020) Table 28. Global Angiongenesis Inhibitors and Stimulators Revenue Market Share by Type (2021-2026) Table 29. Global Angiongenesis Inhibitors and Stimulators Market Size Share by Application (2015-2020) Table 30. Global Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 31. Global Angiongenesis Inhibitors and Stimulators Market Size Share by Application (2021-2026) Table 32. North America Key Players Angiongenesis Inhibitors and Stimulators Revenue (2019-2020) (Million US$) Table 33. North America Key Players Angiongenesis Inhibitors and Stimulators Market Share (2019-2020) Table 34. North America Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 35. North America Angiongenesis Inhibitors and Stimulators Market Share by Type (2015-2020) Table 36. North America Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 37. North America Angiongenesis Inhibitors and Stimulators Market Share by Application (2015-2020) Table 38. Europe Key Players Angiongenesis Inhibitors and Stimulators Revenue (2019-2020) (Million US$) Table 39. Europe Key Players Angiongenesis Inhibitors and Stimulators Market Share (2019-2020) Table 40. Europe Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 41. Europe Angiongenesis Inhibitors and Stimulators Market Share by Type (2015-2020) Table 42. Europe Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 43. Europe Angiongenesis Inhibitors and Stimulators Market Share by Application (2015-2020) Table 44. China Key Players Angiongenesis Inhibitors and Stimulators Revenue (2019-2020) (Million US$) Table 45. China Key Players Angiongenesis Inhibitors and Stimulators Market Share (2019-2020) Table 46. China Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 47. China Angiongenesis Inhibitors and Stimulators Market Share by Type (2015-2020) Table 48. China Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 49. China Angiongenesis Inhibitors and Stimulators Market Share by Application (2015-2020) Table 50. Japan Key Players Angiongenesis Inhibitors and Stimulators Revenue (2019-2020) (Million US$) Table 51. Japan Key Players Angiongenesis Inhibitors and Stimulators Market Share (2019-2020) Table 52. Japan Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 53. Japan Angiongenesis Inhibitors and Stimulators Market Share by Type (2015-2020) Table 54. Japan Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 55. Japan Angiongenesis Inhibitors and Stimulators Market Share by Application (2015-2020) Table 56. Southeast Asia Key Players Angiongenesis Inhibitors and Stimulators Revenue (2019-2020) (Million US$) Table 57. Southeast Asia Key Players Angiongenesis Inhibitors and Stimulators Market Share (2019-2020) Table 58. Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 59. Southeast Asia Angiongenesis Inhibitors and Stimulators Market Share by Type (2015-2020) Table 60. Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 61. Southeast Asia Angiongenesis Inhibitors and Stimulators Market Share by Application (2015-2020) Table 62. India Key Players Angiongenesis Inhibitors and Stimulators Revenue (2019-2020) (Million US$) Table 63. India Key Players Angiongenesis Inhibitors and Stimulators Market Share (2019-2020) Table 64. India Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 65. India Angiongenesis Inhibitors and Stimulators Market Share by Type (2015-2020) Table 66. India Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 67. India Angiongenesis Inhibitors and Stimulators Market Share by Application (2015-2020) Table 68. Central & South America Key Players Angiongenesis Inhibitors and Stimulators Revenue (2019-2020) (Million US$) Table 69. Central & South America Key Players Angiongenesis Inhibitors and Stimulators Market Share (2019-2020) Table 70. Central & South America Angiongenesis Inhibitors and Stimulators Market Size by Type (2015-2020) (Million US$) Table 71. Central & South America Angiongenesis Inhibitors and Stimulators Market Share by Type (2015-2020) Table 72. Central & South America Angiongenesis Inhibitors and Stimulators Market Size by Application (2015-2020) (Million US$) Table 73. Central & South America Angiongenesis Inhibitors and Stimulators Market Share by Application (2015-2020) Table 74. Abbott Laboratories Company Details Table 75. Abbott Laboratories Business Overview Table 76. Abbott Laboratories Product Table 77. Abbott Laboratories Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 78. Abbott Laboratories Recent Development Table 79. Adnexus Therapeutics Company Details Table 80. Adnexus Therapeutics Business Overview Table 81. Adnexus Therapeutics Product Table 82. Adnexus Therapeutics Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 83. Adnexus Therapeutics Recent Development Table 84. F. Hoffman-La Roche Company Details Table 85. F. Hoffman-La Roche Business Overview Table 86. F. Hoffman-La Roche Product Table 87. F. Hoffman-La Roche Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 88. F. Hoffman-La Roche Recent Development Table 89. Genentech Company Details Table 90. Genentech Business Overview Table 91. Genentech Product Table 92. Genentech Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 93. Genentech Recent Development Table 94. Amgen Company Details Table 95. Amgen Business Overview Table 96. Amgen Product Table 97. Amgen Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 98. Amgen Recent Development Table 99. AstraZeneca Company Details Table 100. AstraZeneca Business Overview Table 101. AstraZeneca Product Table 102. AstraZeneca Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 103. AstraZeneca Recent Development Table 104. Novartis Company Details Table 105. Novartis Business Overview Table 106. Novartis Product Table 107. Novartis Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 108. Novartis Recent Development Table 109. Pfizer Business Overview Table 110. Pfizer Product Table 111. Pfizer Company Details Table 112. Pfizer Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 113. Pfizer Recent Development Table 114. Chugai Pharmaceutical Company Details Table 115. Chugai Pharmaceutical Business Overview Table 116. Chugai Pharmaceutical Product Table 117. Chugai Pharmaceutical Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 118. Chugai Pharmaceutical Recent Development Table 119. EntreMed Company Details Table 120. EntreMed Business Overview Table 121. EntreMed Product Table 122. EntreMed Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 123. EntreMed Recent Development Table 124. Eyetech Company Details Table 125. Eyetech Business Overview Table 126. Eyetech Product Table 127. Eyetech Revenue in Angiongenesis Inhibitors and Stimulators Business (2015-2020) (Million US$) Table 128. Eyetech Recent Development Table 129. Research Programs/Design for This Report Table 130. Key Data Information from Secondary Sources Table 131. Key Data Information from Primary Sources List of Figures Figure 1. Global Angiongenesis Inhibitors and Stimulators Market Share by Type: 2020 VS 2026 Figure 2. Sprouting Angiogenesis Features Figure 3. Intussusceptive Angiogenesis Features Figure 4. Global Angiongenesis Inhibitors and Stimulators Market Share by Application: 2020 VS 2026 Figure 5. Hospitals Case Studies Figure 6. Clinics Case Studies Figure 7. Other Case Studies Figure 8. Angiongenesis Inhibitors and Stimulators Report Years Considered Figure 9. Global Angiongenesis Inhibitors and Stimulators Market Size YoY Growth 2015-2026 (US$ Million) Figure 10. Global Angiongenesis Inhibitors and Stimulators Market Share by Regions: 2020 VS 2026 Figure 11. Global Angiongenesis Inhibitors and Stimulators Market Share by Regions (2021-2026) Figure 12. Porter's Five Forces Analysis Figure 13. Global Angiongenesis Inhibitors and Stimulators Market Share by Players in 2019 Figure 14. Global Top Angiongenesis Inhibitors and Stimulators Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Angiongenesis Inhibitors and Stimulators as of 2019 Figure 15. The Top 10 and 5 Players Market Share by Angiongenesis Inhibitors and Stimulators Revenue in 2019 Figure 16. North America Angiongenesis Inhibitors and Stimulators Market Size YoY Growth (2015-2020) (Million US$) Figure 17. Europe Angiongenesis Inhibitors and Stimulators Market Size YoY Growth (2015-2020) (Million US$) Figure 18. China Angiongenesis Inhibitors and Stimulators Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Japan Angiongenesis Inhibitors and Stimulators Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size YoY Growth (2015-2020) (Million US$) Figure 21. India Angiongenesis Inhibitors and Stimulators Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Central & South America Angiongenesis Inhibitors and Stimulators Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018 Figure 24. Abbott Laboratories Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 25. Adnexus Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. Adnexus Therapeutics Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 27. F. Hoffman-La Roche Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. F. Hoffman-La Roche Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 29. Genentech Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Genentech Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 31. Amgen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Amgen Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 33. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. AstraZeneca Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 35. Novartis Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Novartis Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 37. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Pfizer Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 39. Chugai Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Chugai Pharmaceutical Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 41. EntreMed Total Revenue (US$ Million): 2019 Compared with 2018 Figure 42. EntreMed Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 43. Eyetech Total Revenue (US$ Million): 2019 Compared with 2018 Figure 44. Eyetech Revenue Growth Rate in Angiongenesis Inhibitors and Stimulators Business (2015-2020) Figure 45. Bottom-up and Top-down Approaches for This Report Figure 46. Data Triangulation Figure 47. Key Executives Interviewed

Abbott Laboratories Adnexus Therapeutics F. Hoffman-La Roche Genentech Amgen AstraZeneca Novartis Pfizer Chugai Pharmaceutical EntreMed Eyetech